NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 110 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $57,442,000 | -13.9% | 3,766,666 | 0.0% | 39.74% | -8.2% |
| Q4 2021 | $66,708,000 | -15.7% | 3,766,666 | 0.0% | 43.30% | -1.9% |
| Q3 2021 | $79,175,000 | +6.6% | 3,766,666 | 0.0% | 44.14% | +549.2% |
| Q2 2021 | $74,279,000 | -32.2% | 3,766,666 | 0.0% | 6.80% | -35.4% |
| Q1 2021 | $109,497,000 | -4.0% | 3,766,666 | 0.0% | 10.53% | -82.5% |
| Q4 2020 | $114,111,000 | +90.4% | 3,766,666 | 0.0% | 60.06% | +20.4% |
| Q3 2020 | $59,928,000 | -19.4% | 3,766,666 | 0.0% | 49.90% | +3.6% |
| Q2 2020 | $74,354,000 | +60.1% | 3,766,666 | 0.0% | 48.16% | +2.9% |
| Q1 2020 | $46,443,000 | -33.3% | 3,766,666 | 0.0% | 46.79% | -11.6% |
| Q4 2019 | $69,646,000 | +33.5% | 3,766,666 | -0.0% | 52.94% | +21.2% |
| Q3 2019 | $52,168,000 | -5.4% | 3,766,667 | 0.0% | 43.68% | +14.2% |
| Q2 2019 | $55,144,000 | – | 3,766,667 | – | 38.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 18,136,735 | $237,228,000 | 52.50% |
| Ponoi II Management, LLC | 1,298,908 | $16,990,000 | 44.41% |
| Ponoi Management, LLC | 1,298,908 | $16,990,000 | 23.20% |
| Euclidean Capital LLC | 746,674 | $9,766,000 | 9.07% |
| StepStone Group LP | 1,573,357 | $20,580,000 | 2.93% |
| Logos Global Management LP | 850,000 | $11,118,000 | 1.37% |
| First Light Asset Management, LLC | 955,505 | $12,498,000 | 1.26% |
| GREAT POINT PARTNERS LLC | 316,256 | $4,137,000 | 1.00% |
| Rubric Capital Management LP | 877,161 | $11,473,000 | 0.58% |
| Avidity Partners Management LP | 1,798,100 | $23,519,000 | 0.48% |